American corporation's patenting of breast cancer gene overturned
8 Oct 2007
A controversial patent, granted to Myriad Genetics in 2001, which laid claim to a gene indicative of predisposition to breast cancer, has been scrapped for good, it was reported in the Telegraph today.
EP699754 ensured a monopoly on testing for BRCA1 and meant that Myriad could charge up to $3000 for testing. After six years of opposition from scientists and patients alike, the European Patent Office (EPO) ruled that the corporation did not have a justified claim of ownership and that the patent would hinder further research.
Tests for BRCA1 are now expected to decrease to less than $1000 (around £500).
EPO’s decision has been welcomed by both scientists and patients; being seen as a landmark for the greater good over financial gain.
Your donations help us do more
We are an independent charity and are not backed by a large company or society. We raise every penny ourselves to improve the standards of cancer care through education. You can help us continue our work to address inequalities in cancer care by making a donation.
Any donation, however small, contributes directly towards the costs of creating and sharing free oncology education.
Together we can get better outcomes for patients by tackling global inequalities in access to the results of cancer research.
Thank you for your support.